E. Charpentier

发表

Parallel derivation of isogenic human primed and naive induced pluripotent stem cells

T. Mikkelsen, R. Redon, B. Schwikowski, 2018, Nature Communications.

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma

E. Charpentier, M. Glenn, T. Martin, 2019, Blood Cancer Journal.

A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma.

E. Charpentier, M. Glenn, T. Martin, 2014 .

Genetic association analyses highlight IL6, ALPL, and NAV1 as three new susceptibility genes underlying calcific aortic valve stenosis

Y. Bossé, R. Redon, C. Dina, 2019, bioRxiv.

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

E. Winer, N. Robert, R. Carlson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An intermediate level of CD161 expression defines a novel activated, inflammatory, and pathogenic subset of CD8+ T cells involved in multiple sclerosis.

P. Gourraud, Stéphanie Kilens, S. Nedellec, 2017, Journal of autoimmunity.

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics

R. Paridaens, A. Jager, J. Verweij, 2019, Breast Cancer Research and Treatment.

Targeted resequencing identifies TRPM4 as a major gene predisposing to progressive familial heart block type I.

R. Redon, C. Dina, N. Makita, 2016, International journal of cardiology.

De Novo Truncating Mutations in the Kinetochore‐Microtubules Attachment Gene CHAMP1 Cause Syndromic Intellectual Disability

R. Redon, J. Rosenfeld, C. Dina, 2016, Human mutation.

Ex Vivo Expanded Human Non-Cytotoxic CD8+CD45RClow/− Tregs Efficiently Delay Skin Graft Rejection and GVHD in Humanized Mice

Stéphanie Kilens, D. Meistermann, E. Charpentier, 2018, Front. Immunol..

Killer Immunoglobulin-Like Receptor Allele Determination Using Next-Generation Sequencing Technology

C. Retière, E. Charpentier, K. Gagne, 2017, Front. Immunol..

Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death

R. Redon, E. Behr, D. Roden, 2013, Nature Genetics.

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

J. Baselga, N. Harbeck, N. Radosevic-Robin, 2015, Breast Cancer Research and Treatment.

Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells.

Stéphanie Kilens, D. Meistermann, E. Charpentier, 2017, JCI insight.

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

R. Vij, A. Lesokhin, P. Munster, 2017, Blood.

De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause Intellectual Disability.

Meghan C Towne, Sharyn A. Lincoln, Stephan J Sanders, 2017, American journal of human genetics.

Genetic Association Analyses Highlight IL6, ALPL, and NAV1 As 3 New Susceptibility Genes Underlying Calcific Aortic Valve Stenosis.

Y. Bossé, R. Redon, C. Dina, 2019, Circulation. Genomic and precision medicine.

Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility

R. Redon, K. Strauch, P. Lambiase, 2022, Nature Genetics.

Search for Rare Copy-Number Variants in Congenital Heart Defects Identifies Novel Candidate Genes and a Potential Role for FOXC1 in Patients With Coarctation of the Aorta

R. Redon, C. Dina, E. Charpentier, 2016, Circulation. Cardiovascular genetics.

Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death

Dan M Roden, Beverley Balkau, Pierre Lindenbaum, 2013, Nature Genetics.

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma

E. Charpentier, M. Glenn, T. Martin, 2019, Blood Cancer Journal.

Induction of Human Trophoblast Stem Cells from Somatic Cells and Pluripotent Stem Cells.

Stéphanie Kilens, D. Meistermann, C. Chariau, 2020, Cell reports.

Genetic population structure across Brittany and the downstream Loire basin provides new insights on the demographic history of Western Europe

Edith Le Floch, Aude Saint Pierre, R. Redon, 2022, bioRxiv.

3’ RNA sequencing for robust and low-cost gene expression profiling

R. Redon, D. Meistermann, E. Charpentier, 2021 .

A consistent arrhythmogenic trait in Brugada syndrome cellular phenotype

R. Redon, F. Charpentier, V. Probst, 2021, Clinical and translational medicine.

A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A. Iasonos, P. Sabbatini, C. Aghajanian, 2015, International Journal of Gynecologic Cancer.

A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).

K Miller, E. Winer, R. Carlson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fine-scale human genetic structure in Western France

R. Redon, C. Dina, B. Balkau, 2014, European Journal of Human Genetics.

Generation of human induced trophoblast stem cells

Stéphanie Kilens, D. Meistermann, C. Chariau, 2020, bioRxiv.

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

M. Dimopoulos, R. Vij, P. Hari, 2020, Leukemia.

A phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.

R. Vij, D. Benson, E. Charpentier, 2014 .

ICARIA-MM study: efficacy analysis according to prior lines of treatment

P. Richardson, S. Bringhen, Y. Koh, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Transcriptomic Analysis Reveals the Inability of Recombinant AAV8 to Activate Human Monocyte-Derived Dendritic Cells

E. Charpentier, J. Dupont, O. Adjali, 2023, International journal of molecular sciences.

SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).

J. Baselga, F. Penault-Llorca, A. Lluch, 2012 .

A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts.

R. Vij, D. Benson, E. Charpentier, 2016 .